Time course of viremia and antibody seroconversion following human immunodeficiency virus exposure

American Journal of Medicine

Volumn 102, Issue 5 B, 1997, Pages 117-124

  Busch, Michael P ^a,c   Satten, Glen A ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c Blood Centers of the Pacific   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; VIRUS RNA;

BLOOD DONOR; BLOOD TRANSFUSION; CLINICAL PROTOCOL; CONFERENCE PAPER; ENZYME IMMUNOASSAY; HEALTH CARE PERSONNEL; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; OCCUPATIONAL EXPOSURE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECIPIENT; SEROCONVERSION; TIME; VIREMIA; VIRUS REPLICATION;

ANIMALS; DISEASE MODELS, ANIMAL; HEALTH PERSONNEL; HIV ANTIBODIES; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; OCCUPATIONAL EXPOSURE; TIME FACTORS; VIREMIA;

EID: 0030795491     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(97)00077-6     Document Type: Conference Paper

References (43)

1. Gerberding JL. Management of occupational exposures to blood-borne viruses. N Engl Med. 1995;332:444-451.
2. Centers for Disease Control and Prevention. Public Health Service statement on management of occupational exposure to human immunodeficiency virus, including considerations regarding zidovudine postexposure use. MMWR. 1990;39(RR-1):1-14.
3. Update: Provisional Public Health Service recommendations for chemoprophylaxis after occupational exposure to HIV. MMWR. 1996;45:468-472.
4. Centers for Disease Control and Prevention. Case-control study of HIV seroconversion in health-care workers after percutaneous exposure to HIV-infected blood - France, United Kingdom, and United States, January 1988-August 1994. MMWR. 1995;44:929-933.
5. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1996. (Consensus Statement.) JAMA. 1996;276:146-154.
6. Kinloch-de Loës S, Hirschel BJ, Hoen B, et al. A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med. 1995;333:408-413.
7. O'Brien TR, Blattner WA, Waters D, et al. Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study. JAMA. 1996;276:105-110.
8. Henrard DR, Phillips JF, Muenz LR, et al. Natural history of HIV-1 cell-free viremia. JAMA. 1995;274:554-558.
9. Mellors JW, Kingsley LA, Rinaldo CR, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med. 1995;122:573-579.
10. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med. 1994;331:1173-1180.
11. Dickover RE, Garratty EM, Herman SA, et al. Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission: effect of maternal zidovudine treatment on viral load. JAMA. 1996;275:599-605.
12. Lee T-H, Sakahara NS, Fiebig EW, et al. Correlation of HIV-1 RNA levels in serum and heterosexual transmission of HIV-1 from infected transfusion recipients. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;12:427-428.
13. Niu MT, Stein DS, Schnittman SM. Primary human immunodeficiency virus type 1 infection: review of pathogenesis and early treatment intervention in humans and animal retrovirus infections. J Infect Dis. 1993;168: 1490-1501.
14. Clark SJ, Saag MS, Decker WD, et al. High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. N Engl J Med. 1991;324:954-960.
15. Daar ES, Moudgil T, Meyer RD, Ho DD. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N Engl J Med. 1991;324:961-964.
16. Pang S, Shlesinger Y, Daar ES, et al. Rapid generation of sequence variation during primary HIV-1 infection. AIDS. 1992;6:453-460.
17. Zhu T, Mo H, Wang N, et al. Genotypic and phenotypic characterization of HIV-1 in patients with primary infection. Science. 1993;261:1179-1181.
18. Roos MTHL, Lange JMA, de Goede REY, et al. Viral phenotype and immune response in primary human immunodeficiency virus type 1 infection. J Infect Dis. 1992;165:427-432.
19. Cossarizza A, Ortolani C, Mussini C, et al. Massive activation of immune cells with an intact T cell repertoire in acute human immunodeficiency virus syndrome. J Infect Dis. 1995;172:105-112.
20. Roos MTHL, de Leeuw NASM, Claessen FAP, et al. Viro-immunological studies in acute HIV-1 infection. AIDS. 1994;8:1533-1538.
21. Zhu T, Wang N, Carr A, et al. Genetic characterization of human immunodeficiency virus type 1 in blood and genital secretions: evidence for viral compartmentalization and selection during sexual transmission. J Virol. 1996;70:3098-3107.
22. Wolfs TFW, Zwart G, Bakker M, Goldsmith J. HIV-1 genomic RNA diversification following sexual and parenteral virus transmission. Virology. 1992;189:103-110.
23. Cornelissen M, Mulder-Kamping G, Veenstra J, et al. Syncytium-inducing (SI) phenotype suppression at seroconversion after intramuscular inoculation of a non-syncytium-inducing/SI phenotypically mixed human immunodeficiency virus population. J Virol. 1995;69:1810-1818.
24. Henrard DR, Daar E, Farzadegan H, et al. Virologic and immunologic characterization of symptomatic and asymptomatic primary HIV-1 infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;9:305-310.
25. Dorrucci M, Rezza G, Vlahov D, et al. Clinical characteristics and prognostic value of acute retroviral syndrome among injecting drug users. AIDS. 1995;9:597-604.
26. Nara PL. Humoral immunity to HIV-1. Lethal force or Trojan horse? In Gupta S, ed. Immunology of HIV Infection. New York: Plenum Press, 1996:243-276.
27. Horsburgh CR, Ou CH, Jason J, et al. Duration of human immunodeficiency virus infection before detection of antibody. Lancet. 1989;ii:637-639.
28. Petersen LR, Satten GA, Dodd R. Duration of time from onset of human immunodeficiency virus type 1 infectiousness to development of detectable antibody. Transfusion. 1994;34:283-289.
29. Satten G. Upper and lower bound distributions that give simultaneous confidence intervals for quantiles. J Am Stat Assoc. 1995;90:747-752.
30. Busch MP, Lee LLL, Satten GA, et al. Time course of detection of viral and serologic markers preceding human immunodeficiency virus type 1 seroconversion: implications for screening of blood and tissue donors. Transfusion. 1995;35:91-97.
31. Wolinsky SM, Korber BTM, Neumann AU, et al. Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection. Science. 1996;272:537-542.
32. Busch MP, Herman SA, Henrard DR, et al. Time course and kinetics of HIV viremia during primary infection. (Abstr. 38.) 3rd National Conference on Human Retroviruses and Related Opportunistic Infections, Washington, DC, January-February 1996. Session 10:60.
33. Busch MP. HIV and blood transfusions: focus on seroconversion. (State of the Art Lecture, International Society of Blood Transfusion, Amsterdam, 1994.) Vox Sang. 1994;67:13-18.
34. Lackritz EM, Satten GA, Aberle-Grasse J, et al. Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States. N Engl J Med. 1995;333:1721-1725.
35. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ, for the NHLBI Retrovirus Epidemiology Blood Donor Study. The risk of transfusion-transmitted viral infections. N Engl J Med. 1996;334:1685-1690.
36. AuBuchon JP, Birkmeyer JD, Busch MP. Cost-effectiveness of expanded HIV test protocols for donated blood. Transfusion. 1997;37:45-51.
37. Zaaijer HL, v Exel-Oehlers P, Kraijeveld T, Altena F, Lelie PN. Early detection of antibodies to HIV-1 by third-generation assays. Lancet. 1992;340:770-772.
38. Constantine NT, van der Groen G, Belsey EM, Tamashiro H. Sensitivity of HIV-antibody assays determined by seroconversion panels. AIDS. 1994;8:1715-1720.
39. Herman SA, Sakahara N, Garrett P, Schumacher RT, Busch M. Determination of HIV growth kinetics during primary infection by analysis of viral burden in seroconverters. (Abstr. We.B. 530.) XI International Conference on AIDS, Vancouver, BC, Canada, July 1996. Vol. II:28.
40. Miller CJ, Alexander NJ, Vogel P, Anderson J, Marx PA. Mechanism of genital transmission of SIV: a hypothesis based on transmission studies and the location of SIV in the genital tract of chronically infected female rhesus macaques. J Med Primatol. 1992;21:64-68.
41. Miller CJ, McGhee JR, Gardner MB. Mucosal immunity, HIV transmission and AIDS. Lab Invest. 1992;68:129-145.
42. Miller CJ, McGhee JR. Progress towards a vaccine to prevent sexual transmission of HIV. (Review.) Nat Med. 1996;2:751-752.
43. Simard C, Huang M, Jolicouer P. Murine AIDS is initiated in the lymph nodes draining the site of inoculation, and the infected B cells influence T cells loaved at distance, in noninfected organs. J Virol. 1994;68:1903-1912.